CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
Stanford University
Poseida Therapeutics, Inc.
LTZ Therapeutics, Inc.
Verismo Therapeutics
University Health Network, Toronto
University of Arizona
Mayo Clinic
Chengdu Zenitar Biomedical Technology Co., Ltd
University of Nebraska
Florida International University
ImmunityBio, Inc.
Nkarta, Inc.
Juno Therapeutics, a Subsidiary of Celgene
Athenex, Inc.
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
University of Louisville
Dana-Farber Cancer Institute
University of Alabama at Birmingham
Morphotek
National Cancer Institute (NCI)
Children's Hospital of Philadelphia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Cellerant Therapeutics
Children's Oncology Group
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Boston Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Enzon Pharmaceuticals, Inc.